Skip to main content
C

CELLUMED CO., LTD. — Investor Relations & Filings

Ticker · 049180 ISIN · KR7049180003 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2026-01-06 Legal Proceedings Report
Country KR South Korea
Listing KO 049180

About CELLUMED CO., LTD.

http://www.clnzyme.co.kr/

CELLUMED CO., LTD. is a biotechnology company specializing in the development and manufacturing of medical devices, tissue grafts, and advanced biologics. The company operates as a human tissue bank, producing and supplying a variety of bone graft materials, including allografts and xenografts, for transplantation. Its medical device portfolio features orthopedic implants, with a key product being an artificial knee joint system. In the biologics sector, Cellumed develops growth factors and provides specialized enzymes, such as CLnZyme, which are utilized in the research, development, and production of RNA-based vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
[기재정정]투자판단관련주요경영사항 (집행판결 청구소송 합의 변경의 건)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory filing from the Korean Exchange (KRX) system (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details a change in the terms of a settlement agreement related to a legal judgment (집행판결청구소송). Since this document describes a specific legal settlement and its ongoing financial implications, it falls under the category of legal proceedings and regulatory updates. Given the specific nature of the filing as a 'Major Management Matter' regarding litigation, it is best classified as a Legal Proceedings Report (LTR).
2026-01-06 Korean
[기재정정]투자판단관련주요경영사항 (집행판결 청구소송 합의 변경의 건)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Correction Report' (정정신고) regarding a previous disclosure about a legal settlement ('집행판결청구소송 합의 변경의 건'). It details changes to payment schedules for a legal settlement, which constitutes a significant legal and financial matter. Since it involves ongoing litigation and settlement terms, it falls under the category of Legal Proceedings Report.
2025-12-31 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) for the company Cellumed. It details the amendment of terms for a third-party allocation capital increase, including changes to the payment date, share issuance details, and the identity of the new major shareholder. This falls under the category of announcements regarding new share issues and capital structure changes.
2025-12-29 Korean
[기재정정]경영권변경등에관한계약체결
M&A Activity Classification · 1% confidence The document is a regulatory filing from a Korean company (Cellumed) regarding a 'Correction Report' (정정신고) for a 'Change in Management Control' (경영권 변경 등에 관한 계약 체결). It details the change in the acquiring entity (from L&C ES to TD Landmark Fund 1) and the associated third-party capital increase (유상증자). Since this document is a formal regulatory disclosure regarding corporate control and capital structure changes, it falls under the 'Regulatory Filings' category as it is a specific type of mandatory disclosure that does not fit into the other specialized categories like M&A (which usually refers to corporate mergers/acquisitions of entities rather than internal management control changes via share issuance) or Share Issue (which is a component, but the primary focus here is the management control change).
2025-12-29 Korean
[기재정정]주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange). It details the issuance of new shares, the purpose of the capital raise, and the third-party allocation details. This falls under the category of capital structure changes and financing activities.
2025-12-24 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding a decision to issue new shares (유상증자결정). This type of filing is a formal regulatory disclosure concerning capital structure changes, specifically a third-party allocation capital increase. It fits the definition of a 'Share Issue/Capital Change' (SHA) filing as it details the issuance of new shares, the purpose of the capital raise, and the impact on shareholding structure.
2025-12-23 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.